Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.
The deal includes a $1.6-billion fee if AbbVie tries to walk away.
An international AIDS conference this weekend kicked off a new battle in the war against hepatitis C: demonstrating high cure rates in those who are co-infected.
Less-frequent dosing and competitive pricing could spur a shift in market share among products that treat the hereditary blood disorder.
Parent Project Muscular Dystrophy (PPMD) and allied stakeholders recently gave FDA the first patient advocacy-initiated guidance for a rare disease to help accelerate development and review of potential therapies for Duchenne muscular dystrophy.
What does it take to turn your booth into a world-class educational and entertainment experience? Here are five proven principles that consistently bring the magic to the show floor.
"Behavior design" is beginning to make its way into pharma.
NPR reports that the move has made Sierra Sandison a type 1 diabetes hero and that users have given the Facebook photo over 4,000 "likes."
CEO Severin Schwan tells Reuters that the Swiss firm will be looking for small acquisitions and partnerships.
AbbVie, in the latest example of a US drugmaker seeking to lower its tax rate, said today that it's buying Dublin-based Shire for $54 billion.
Click on the image above to see a gallery of images from the 2013 MM&M Awards dinner
Missed MM&M's Skill Sets Live event on Engaging Patients? We're now giving you a second chance to get up to speed! Click here to access this insightful e-book with all the key take-aways.